OUR JOURNEY

To temporarily alter the barrier characteristics of the elastin-collagen matrix to allow large molecule drugs to be absorbed through the skin into the body.

OUR TEAM

Redefining
Transdermal Delivery

Our team of experts has extensive experience in product development, drug delivery, pre-clinical and clinical pharmacological research, and pharmaceutical and medical device licensing and marketing. We are committed to providing our patients with the highest quality products and services.

Our Board of Directors, senior management, and group of scientific advisors have the expertise and experience to ensure that our products meet the highest standards of safety and efficacy.

Our Journey So Far

2012

HYPOSPRAY IS FOUNDED

The company was formed as a Florida corporation and registered as a "C" corporation capitalized from revenue generated from a wholly-owned subsidiary.

2013

GROUNDBREAKING TRANSDERMAL TECHNOLOGY RESEARCHED

First approvals for clinical studies received and regulatory compliance instructions executed as directed by US FDA.

Our Team.

At HypoSpray Pharma, we’re committed to providing our clients with safe and effective drug delivery services. Our team has over 20 years of experience in the pharmaceutical industry, and we’re passionate about providing our clients with the highest level of quality care.

Kenneth B. Kirby

Chairman & Founder

Bert Moerings

Vice Chairman & CEO

Chandan Alam, MD

CSO & Founder

Long H. Vu, Esq.

COO & Regulatory

David Weild IV, MBA

Director

Edward Borkowski

Director

Technical Advisory Board.

Our team is composed of industry veterans with decades of experience in product development, pre-clinical and clinical pharmacological research, and pharmaceutical manufacturing.

Gordon von Nehring, Ph.D.

Head Formulation, HSP

William D. Kirsh, D.O., M.P.H.

CMO, HSP

Scientific Board

Our team is composed of industry veterans with decades of experience in product development, pre-clinical and clinical pharmacological research, and pharmaceutical manufacturing.

Howard Maibach, MD

Professor of Dermatology, UCSF

Developer of the 21 Cumulative Irritation Test (CIT)

Founder, Science of Dermatotoxicology

Jane Shaw, Ph.D.

CO-developer of the Scopalamine Patch

Co-founder of ALZA

Atholl Johnston, BSc, MSc, Ph.D., FRSPath

Professor Clinical Pharmacology
Barts & the London NHS Queen Mary's School of Medicine & Dentistry, University of London

Director, Analytical Services International Ltd

Former Director Wm. Harvey Research Limited London, England

Richard Langford, BSc MD PhD

Chief Medical OfficerChief Medical Officer

St Pancras Clinical Research

Consultant in Anaesthesia and Pain MedicineConsultant in Anaesthesia and Pain Medicine

Barts and The London NHS Trust